Healthcare Industry News: amikacin
News Release - June 5, 2007
Transave, Inc. Appoints Mich Soga as Chief Financial OfficerMONMOUTH JUNCTION, N.J., June 5 (HSMN NewsFeed) -- Transave Inc., a biopharmaceutical company developing drugs for life-threatening lung diseases, today announced the appointment of Michio "Mich" Soga as Chief Financial Officer.
Mr. Soga brings nearly twenty years of international and domestic corporate finance experience to Transave. He has held various executive positions at Goldman Sachs, Morgan Stanley, and Credit Agricole Indosuez in New York, Tokyo and London. In addition to his considerable corporate finance experience, Mr. Soga has a strong operational background, having served as Chief Financial Officer with Confetti Network, an internet company in the UK and as Interim CFO with Metaphore Pharmaceuticals (since merged with ActivBiotics). Most recently, Mich was the Chief Financial Officer of Pharmacopeia, Inc. (Nasdaq: PCOP ), a biopharmaceutical company developing small molecule therapeutics.
"With his successful track record in investment banking and financial management, Transave has found in Mich Soga, an experienced professional with expertise to complement our team," said Tim Whitten, President and Chief Executive Officer of Transave. "This addition will help us expedite the delivery our lead drug candidates in cystic fibrosis and lung cancer to meet the needs of our patient population."
Mr. Soga holds a Bachelors degree from Dartmouth College, and a Masters of Private and Public Management from the Yale School of Management.
About Transave, Inc.
Transave is a privately-held biotechnology company whose mission is to improve the treatment of serious lung diseases through the development of novel, site-specific liposomal drug products. Transave's product candidates are delivered via inhalation directly to the site of the disease. The company's proprietary liposomal delivery technology provides for prolonged release of a drug in the lung while minimizing systemic exposure, which may improve the therapeutic index of commonly used pharmaceutical products.
Transave has two products in clinical development: Liposomal amikacin for Inhalation (Arikace(TM)) for Pseudomonas aeruginosa infections in cystic fibrosis patients and Cisplatin Lipid Complex for cancers that affect the lung. For more information about Transave's technology and development programs, visit http://www.transaveinc.com/.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.